US Dollar vs MXN

Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.

Regístrate

TGTX TG Therapeutics Inc

13.57

-0.34 (-2.44%)

26 Abr 2024 - Cerrado

Retrasado por 15 minutos

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Article too big to display. Click here to view on the SEC website

TG Therapeutics (NASDAQ:TGTX)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024

Haga Click aquí para más Gráficas TG Therapeutics.

TG Therapeutics (NASDAQ:TGTX)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024

Haga Click aquí para más Gráficas TG Therapeutics.

Noticias sobre TG Therapeutics Inc TGTX

TG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
Jueves 18 de Abril 2024 (1 semana hace) • GlobeNewswire Inc.

TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis
Jueves 18 de Abril 2024 (1 semana hace) • GlobeNewswire Inc.

TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
Lunes 15 de Abril 2024 (2 semanas hace) • GlobeNewswire Inc.

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
Viernes 8 de Marzo 2024 (2 meses hace) • GlobeNewswire Inc.

TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
Viernes 1 de Marzo 2024 (2 meses hace) • GlobeNewswire Inc.

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Jueves 29 de Febrero 2024 (2 meses hace) • Edgar (US Regulatory)

Form 8-K - Current report
Miércoles 28 de Febrero 2024 (2 meses hace) • Edgar (US Regulatory)

TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2023 Financial Results
Miércoles 28 de Febrero 2024 (2 meses hace) • GlobeNewswire Inc.

TG Therapeutics Announces Issuance of Additional Patents for BRIUMVI® (ublituximab-xiiy)
Martes 27 de Febrero 2024 (2 meses hace) • GlobeNewswire Inc.

TG Therapeutics Announces European Launch of BRIUMVI® (ublituximab-xiiy)
Lunes 26 de Febrero 2024 (2 meses hace) • GlobeNewswire Inc.

TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2023 Financial Results and Business Update
Viernes 23 de Febrero 2024 (2 meses hace) • GlobeNewswire Inc.

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
Martes 20 de Febrero 2024 (2 meses hace) • GlobeNewswire Inc.

Más de TG Therapeutics Inc Artículos de Noticias

Deutsche Telekom (QX)

Invesco QQQ Trust Series 1

Delayed Upgrade Clock

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones